Novartis board approves buyback
The board of directors Novartis India on Monday approved buyback of up to 34.5 lakh shares at 670 a share, aggregating to 231.15 crore. In a notice to the exchanges, the company said, the targeted...25-09-2017
25-09-2017
Updates
Sub : Cut-off date for Postal Ballot / E-voting In terms of Sections 108 and 110 of the Companies Act, 2013 and Rule 20 of the Companies (Management & Administration) Rules 2014, the Company will provide its shareholders the facility to exercise their vote for transacting the item of special business via postal ballot and e-voting. The Company would be availing e-voting services of National Securities Depository Limited (NSDL)....25-09-2017
Board approves Buyback of equity shares
Novartis India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on September 25, 2017, (commencement time 10.30 a.m. and conclusion time 01.15 p.m.) unanimously approved a buyback proposal for purchase by the Company of upto 34,50,000 equity shares of Rs. 5/- each (representing 12.26% of the total paid-up equity capital), from all the existing equity shareholders of the Company on the record date on a proportionate...25-09-2017
Outcome of Board Meeting
Outcome of the meeting of Board of Directors of Novartis India Limited ('Company') held on September 25, 2017 - Proposal for Buyback of equity shares of the Company25-09-2017
Novartis collaborates with The Max Foundation to support cancer access programme for people in lowerincome countries
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors23-09-2017
Board to consider Buyback of Equity Shares
Novartis India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on September 25, 2017, to consider a proposal for Buyback of the Company's equity shares, constitution of buyback committee, and appointment of intermediaries in accordance with all applicable provisions of law.20-09-2017
Intimation of Buy back
Pursuant to Regulation 29(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that a meeting of the Board of Directors of the Company will be held on September 25, 2017, to consider a proposal for Buyback of the Company's equity shares, constitution of buyback committee, and appointment of intermediaries in accordance with all applicable provisions of law.20-09-2017
Sandoz announces new data on proposed biosimilar adalimumab
Sandoz, a Novartis division and the pioneer and global leader in biosimilars, announces new data on its proposed biosimilar adalimumab.15-09-2017
US FDA accepts Sandoz BLA for proposed biosimilar rituximab for review
Sandoz, a Novartis Division, and the pioneer and global leader in biosimilars, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k)13-09-2017
Novartis' skin cancer drug posts win in trials, Roche flops
Novartis's mix of Tafinlar and Mekinist slashed the risk of melanoma returning or death by 53%11-09-2017